Company
Pahr Therapeutics, Inc.
PAhR Therapeutics is a clinical-stage company focused on developing novel mechanisms for the treatment of pulmonary arterial hypertension (PAH)
Also known as Pahr Therapeutics
- Business model
- B2B
- Legal name
- PAhR Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
肺動脈性肺高血圧症の創薬開発
Funding snapshot
- Total raised
- $4.7MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Seed, $14M2025-07-28
Funding rounds
- Seed
- $14M2025-07-28, Company stated
- Round, 2025
- $4.7M2025-02-27, SEC form D sold, 4 investors
Loading relationship preview